Some neurological diseases are not diagnosed until a threshold of damage has been surpassed. Nevertheless, molecular biomarkers indicative of early disease are present long before clinical expression of neurological deficits. Identifying biomarkers by molecular imaging therefore shows great promise in the fight against neurological disease.
MSOT can be used to accurately determine the spatial biodistribution of probes in the mouse brain through an intact skin and skull. In combination with specific probes, this provides the capacity to study molecular features of neurological disease in vivo.